Cargando…
Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen
Tamoxifen is a prodrug that is primarily metabolized into the pharmacologically active metabolite endoxifen and eventually into inactive metabolites. The herb curcumin may increase endoxifen exposure by affecting phase II metabolism. We compared endoxifen and tamoxifen exposure in breast cancer pati...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468355/ https://www.ncbi.nlm.nih.gov/pubmed/30909366 http://dx.doi.org/10.3390/cancers11030403 |
_version_ | 1783411415159144448 |
---|---|
author | Hussaarts, Koen G.A.M. Hurkmans, Daan P. Oomen-de Hoop, Esther van Harten, Leonie J. Berghuis, Stan van Alphen, Robbert J. Spierings, Leontine E.A. van Rossum-Schornagel, Quirine C. Vastbinder, Mijntje B. van Schaik, Ron H.N. van Gelder, Teun Jager, Agnes van Leeuwen, Roelof W.F. Mathijssen, Ron H.J. |
author_facet | Hussaarts, Koen G.A.M. Hurkmans, Daan P. Oomen-de Hoop, Esther van Harten, Leonie J. Berghuis, Stan van Alphen, Robbert J. Spierings, Leontine E.A. van Rossum-Schornagel, Quirine C. Vastbinder, Mijntje B. van Schaik, Ron H.N. van Gelder, Teun Jager, Agnes van Leeuwen, Roelof W.F. Mathijssen, Ron H.J. |
author_sort | Hussaarts, Koen G.A.M. |
collection | PubMed |
description | Tamoxifen is a prodrug that is primarily metabolized into the pharmacologically active metabolite endoxifen and eventually into inactive metabolites. The herb curcumin may increase endoxifen exposure by affecting phase II metabolism. We compared endoxifen and tamoxifen exposure in breast cancer patients with or without curcumin, and with addition of the bio-enhancer piperine. Tamoxifen (20–30mg per day (q.d.)) was either given alone, or combined with curcumin (1200 mg three times daily (t.i.d.)) +/− piperine (10 mg t.i.d.). The primary endpoint of this study was the difference in geometric means for the area under the curve (AUC) of endoxifen. Genotyping was performed to determine CYP2D6 and CYP3A4 phenotypes. The endoxifen AUC(0–24h) decreased with 7.7% (95%CI: −15.4 to 0.7%; p = 0.07) with curcumin and 12.4% (95%CI: −21.9 to −1.9%; p = 0.02) with curcumin and piperine, compared to tamoxifen alone. Tamoxifen AUC(0–24h) showed similar results. For patients with an extensive CYP2D6 metabolism phenotype (EM), effects were more pronounced than for intermediate CYP2D6 metabolizers (IMs). In conclusion, the exposure to tamoxifen and endoxifen was significantly decreased by concomitant use of curcumin (+/− piperine). Therefore, co-treatment with curcumin could lower endoxifen concentrations below the threshold for efficacy (potentially 20–40% of the patients), especially in EM patients. |
format | Online Article Text |
id | pubmed-6468355 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64683552019-04-24 Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen Hussaarts, Koen G.A.M. Hurkmans, Daan P. Oomen-de Hoop, Esther van Harten, Leonie J. Berghuis, Stan van Alphen, Robbert J. Spierings, Leontine E.A. van Rossum-Schornagel, Quirine C. Vastbinder, Mijntje B. van Schaik, Ron H.N. van Gelder, Teun Jager, Agnes van Leeuwen, Roelof W.F. Mathijssen, Ron H.J. Cancers (Basel) Article Tamoxifen is a prodrug that is primarily metabolized into the pharmacologically active metabolite endoxifen and eventually into inactive metabolites. The herb curcumin may increase endoxifen exposure by affecting phase II metabolism. We compared endoxifen and tamoxifen exposure in breast cancer patients with or without curcumin, and with addition of the bio-enhancer piperine. Tamoxifen (20–30mg per day (q.d.)) was either given alone, or combined with curcumin (1200 mg three times daily (t.i.d.)) +/− piperine (10 mg t.i.d.). The primary endpoint of this study was the difference in geometric means for the area under the curve (AUC) of endoxifen. Genotyping was performed to determine CYP2D6 and CYP3A4 phenotypes. The endoxifen AUC(0–24h) decreased with 7.7% (95%CI: −15.4 to 0.7%; p = 0.07) with curcumin and 12.4% (95%CI: −21.9 to −1.9%; p = 0.02) with curcumin and piperine, compared to tamoxifen alone. Tamoxifen AUC(0–24h) showed similar results. For patients with an extensive CYP2D6 metabolism phenotype (EM), effects were more pronounced than for intermediate CYP2D6 metabolizers (IMs). In conclusion, the exposure to tamoxifen and endoxifen was significantly decreased by concomitant use of curcumin (+/− piperine). Therefore, co-treatment with curcumin could lower endoxifen concentrations below the threshold for efficacy (potentially 20–40% of the patients), especially in EM patients. MDPI 2019-03-22 /pmc/articles/PMC6468355/ /pubmed/30909366 http://dx.doi.org/10.3390/cancers11030403 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hussaarts, Koen G.A.M. Hurkmans, Daan P. Oomen-de Hoop, Esther van Harten, Leonie J. Berghuis, Stan van Alphen, Robbert J. Spierings, Leontine E.A. van Rossum-Schornagel, Quirine C. Vastbinder, Mijntje B. van Schaik, Ron H.N. van Gelder, Teun Jager, Agnes van Leeuwen, Roelof W.F. Mathijssen, Ron H.J. Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen |
title | Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen |
title_full | Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen |
title_fullStr | Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen |
title_full_unstemmed | Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen |
title_short | Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen |
title_sort | impact of curcumin (with or without piperine) on the pharmacokinetics of tamoxifen |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468355/ https://www.ncbi.nlm.nih.gov/pubmed/30909366 http://dx.doi.org/10.3390/cancers11030403 |
work_keys_str_mv | AT hussaartskoengam impactofcurcuminwithorwithoutpiperineonthepharmacokineticsoftamoxifen AT hurkmansdaanp impactofcurcuminwithorwithoutpiperineonthepharmacokineticsoftamoxifen AT oomendehoopesther impactofcurcuminwithorwithoutpiperineonthepharmacokineticsoftamoxifen AT vanhartenleoniej impactofcurcuminwithorwithoutpiperineonthepharmacokineticsoftamoxifen AT berghuisstan impactofcurcuminwithorwithoutpiperineonthepharmacokineticsoftamoxifen AT vanalphenrobbertj impactofcurcuminwithorwithoutpiperineonthepharmacokineticsoftamoxifen AT spieringsleontineea impactofcurcuminwithorwithoutpiperineonthepharmacokineticsoftamoxifen AT vanrossumschornagelquirinec impactofcurcuminwithorwithoutpiperineonthepharmacokineticsoftamoxifen AT vastbindermijntjeb impactofcurcuminwithorwithoutpiperineonthepharmacokineticsoftamoxifen AT vanschaikronhn impactofcurcuminwithorwithoutpiperineonthepharmacokineticsoftamoxifen AT vangelderteun impactofcurcuminwithorwithoutpiperineonthepharmacokineticsoftamoxifen AT jageragnes impactofcurcuminwithorwithoutpiperineonthepharmacokineticsoftamoxifen AT vanleeuwenroelofwf impactofcurcuminwithorwithoutpiperineonthepharmacokineticsoftamoxifen AT mathijssenronhj impactofcurcuminwithorwithoutpiperineonthepharmacokineticsoftamoxifen |